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actions were found to methylprednisolone sodium hemi-
succinate (MSH) and prednisolone sodium hemisuccinate 
(PSH). In contrast, nonsuccinylated corticosteroids (includ-
ing methylprednisolone and prednisolone in one patient) 
yielded no test reactions. Basophils from one patient exhib-
ited a stimulated expression of the activation marker CD63 
upon in vitro incubation with PSH or hydrocortisone sodium 
succinate, but not with hydrocortisone. Skin tests and baso-
phil activation tests were negative in controls. One patient 
was challenged with the incriminated drugs. He developed 
flush, conjunctivitis, tachycardia and dyspnea 2 min after in-
jection of MSH, and dyspnea shortly after intravenous ad-
ministration of PSH. Oral and intravenous challenge tests 
with nonsuccinylated corticosteroids were tolerated well by 
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 Abstract 
 Background: Despite their frequent use, systemic cortico-
steroids have rarely elicited immediate-type reactions.  Ob-
jective: We report two male patients, aged 26 and 70 years, 
respectively, with severe immediate-type hypersensitivity 
secondary to the administration of corticosteroids esterified 
with succinate.  Methods: Skin tests, basophil activation tests 
and challenge tests were performed for diagnostic evalu-
ation.  Results: In both patients, immediate-type skin test re-
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 Established Facts 
 • In recent years, immediate-type reactions to succinylated corticosteroids, probably related to the suc-
cinate moiety, have been reported quite frequently. 
 Novel Insights 
 • This case report reviews present knowledge on immediate-type reactions to succinylated corticoste-
roids and highlights the role of the basophil activation test, a helpful diagnostic tool in identifying 
the causative agents. 
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both patients.  Conclusions: These case reports should alert 
clinicians to rare, but severe immediate-type reactions to 
corticosteroids, related to the succinate moiety in our pa-
tients. In case of allergic reactions to corticosteroids, it is 
mandatory to identify the causative agent and find safe al-
ternatives.  Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Corticosteroids are rarely suspected as causative 
agents of immediate-type hypersensitivity as their anti-
allergic properties would seem to contradict their ca-
pacity to induce such reactions. However, worsening of 
allergic symptoms during corticosteroid therapy may 
not always indicate treatment failure. Therefore, the 
possibility of corticosteroid hypersensitivity has to be 
considered.
 Immediate-type reactions such as sneezing, angio-
edema, generalized urticaria, bronchospasm, hypoten-
sion or even anaphylactic shock have been observed after 
oral, intravenous, intramuscular, subcutaneous, or in-
tra-articular administration of corticosteroids  [1] . Ap-
proximately 100 cases of immediate-type hypersensitiv-
ity to corticosteroids have been reported  [1–3] . The 
pathomechanism of these reactions has remained un-
clear in most patients, but positive skin test reactions or 
specific IgE antibodies to the suspected elicitors were 
found in some patients  [3–17] . Challenge tests were per-
formed in just a few cases, and most of them were posi-
tive  [5, 8, 14, 18–20] .
 We here report two patients with immediate-type re-
actions to corticosteroids whose test results indicate im-
mediate-type allergy to the succinate moiety of succinyl-
ated corticosteroids to be the underlying pathomecha-
nism of hypersensitivity.
 Case Report 
 Patient 1 
 History 
 In 2000, a then 26-year-old male developed flush and dyspnea 
after being stung by a yellow jacket. He received an intravenous 
injection of prednisolone sodium hemisuccinate (PSH, Solu-
Decortin  H), whereupon his symptoms worsened. In 2004, he 
again experienced a systemic reaction after a yellow jacket sting, 
and was treated with intravenous methylprednisolone sodium 
hemisuccinate (MSH, Urbason  solubile), clemastine fumarate 
(Tavegil  ) and presumably dimethindene maleate (Fenistil  ). He 
developed anaphylactic shock within 15 min after administration 
of these drugs. The patient recovered from both episodes without 
sequelae. Skin examination revealed no manifestations of masto-
cytosis; baseline serum tryptase concentration was 8.3   g/l (95th 
percentile in normals, 11.4   g/l).
 Allergological Tests 
 Skin prick tests with three commercial injectable corticoste-
roid solutions, i.e. PSH 5 mg/ml (Solu-Decortin H), MSH 1.6 mg/
ml (Urbason solubile) and hydrocortisone sodium succinate 
(HSS) 50 mg/ml (Hydrocortison rotexmedica), induced positive 
reactions (wheal diameter 4 mm) after 20 min; in contrast, neither 
corticosteroids without a succinate moiety, nor other succinylated 
substances, or succinic acid itself (2.5 mg/ml; Sigma-Aldrich  , 
Munich, Germany) yielded positive skin prick test reactions ( ta-
ble 1 ). Histamine dihydrochloride (0.1%) served as positive con-
trol and elicited a positive reaction (wheal diameter 4 mm). There 
was no skin test reaction to physiological saline (negative control). 
In five healthy volunteers, skin prick tests performed as described 
above with PSH, MSH and HSS were negative. In addition, skin 
prick tests with a standard series of common aeroallergens were 
performed in the patient, and revealed positive reactions (wheal 
diameter 3–6 mm) to numerous allergens. Assessment of patient’s 
serum with CAP-FEIA (Phadia, Freiburg, Germany) revealed 
specific IgE antibodies to yellow jacket (16.0 kU/l; CAP class 3) 
and bee venom (0.78 kU/l; CAP class 2), but no specific IgE anti-
bodies to natural rubber latex. Total IgE was 241 kU/l (normal 
range  ! 100 kU/l). A basophil activation test was performed using 
the Flow2 CAST system (Bühlmann Laboratories, Schönenbuch, 
Switzerland). Briefly, EDTA whole blood was incubated with 
prednisolone sodium phosphate, PSH and HSS at different con-
centrations as well as with formyl-methionyl-leucyl-phenylala-
nine (fMLP), which served as positive control, and stimulation 
buffer (negative control). A staining reagent containing monoclo-
nal antibodies to human CD63 (activation marker on basophils) 
labeled with fluorescein isothiocyanate (anti-CD63-FITC) and to 
human chemokine receptor CCR3 (basophil marker) labeled with 
phycoerythrin (anti-CCR3-PE) was added. Cells were then ana-
lyzed by flow cytometry. The corticosteroids did not induce ba-
sophil activation in this test; the positive control yielded a stimu-
lation of 18.15%.
 To prove that PSH and MSH were the eliciting compounds in 
a single-blind manner, placebo-controlled challenge tests were 
performed. In accordance with current guidelines for drug prov-
ocation tests  [21] , incremental doses of PSH (1, 5, 10, 50, 100 mg) 
and MSH (2, 8, 15, 75 mg) were administered intravenously on 
different days at intervals of 90 min after placement of an intra-
venous line and under close monitoring in the intensive care unit 
 [21, 22] . Shortly after administration of 100 mg PSH, the patient 
became dyspneic. Two minutes after injection of 75 mg MSH, he 
developed flush, conjunctivitis, tachycardia and dyspnea. In con-
trast, intravenous challenge tests with a succinate-free corticoste-
roid preparation (dexamethasone sodium phosphate, Dexa-ratio-
pharm  ; maximum single dose: 40 mg), clemastine fumarate 
(Tavegil; maximum single dose: 2 mg) and dimethindene maleate 
(Fenistil; maximum single dose 4 mg) as well as oral challenges 
with betamethasone (Celestamine  N 0.5 liquidum; maximum 
single dose: 9 mg), doxylamine succinate (Sedaplus  Saft; maxi-
mum single dose 30 mg) and  DL -  -tocopheryl acid succinate 
(Merz Spezial Dragees; maximum single dose: 10 mg) were toler-
ated well.
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 Yellow jacket venom immunotherapy was started. In addition, 
he was provided with an emergency kit containing betametha-
sone (Celestamine N 0.5 liquidum) and dimethindene maleate 
(Fenistil) for oral self-application, self-injectable adrenaline (An-
apen  ) and dexamethasone sodium phosphate (Dexa-ratio-
pharm) for intravenous injection by a physician in case of emer-
gency.
 Patient 2 
 History 
 A 70-year-old male patient had received PSH- and HSS-con-
taining preparations intravenously because of acute hearing loss. 
He started to develop nausea and vomiting within seconds, and 
finally he lost consciousness. Emergency treatment including ad-
ministration of adrenaline was performed, and he recovered 
without sequelae. Medical history included stenosis of the carotid 
artery, cardiovascular disease, hypertension and hyperuricemia. 
Skin examination was without pathological findings. Baseline se-
rum tryptase concentration was 5.1   g/l (95th percentile in nor-
mals: 11.4   g/l).
 Allergological Assessment 
 The patient presented 15 years after the reaction. Skin prick 
tests with 4 corticosteroids and succinic acid were negative ( ta-
ble 2 ). Intradermal tests were positive (wheal diameter 12 mm) for 
both PSH 0.5 mg/ml (Solu-Decortin H) and MSH 0.16 mg/ml (Ur-
bason solubile) (wheal diameter 10 mm) whereas intradermal 
tests with HSS 0.5 mg/ml (Hydrocortison rotexmedica) and tri-
amcinolone acetonide dipotassium phosphate 1 mg/ml (Volon  
A solubile) yielded negative results. There was no skin test reac-
Table 1.  Test results in patient 1
Agent Preparation Skin prick test Challenge test
Prednisolone sodium hemisuccinate Solu-Decortin (50 mg/ml) 4 mm (5 mg/ml) positive (max. single dose 100 mg, i.v.)
Methylprednisolone sodium hemisuccinate Urbason solubile (16 mg/ml) 4 mm (1.6 mg/ml) positive (max. single dose 75 mg, i.v.)
Hydrocortisone sodium succinate Hydrocortison rotexmedica (50 mg/ml) 4 mm (50 mg/ml) ND
Dexamethasone sodium phosphate Dexa-ratiopharm (8 mg/ml) negative (max. single dose 40 mg, i.v.)
Methylprednisolone Urbason  (40 mg) ND
Prednisolone Decortin H (5 mg) ND
Triamcinolone acetonide dipotassium phosphate Volon A solubile (40 mg/ml) ND
Betamethasone Celestamine N (0.5 mg/ml) negative (max. single dose 9 mg, orally)
Hydrocortisone Hydrocortison Hoechst  (5 mg/ml) ND
Prednisolone sodium phosphate hefasolon i.v. (8 mg/ml) ND
Dl--tocopheryl acid succinate Merz Spezial Dragees (10 mg) negative (max. single dose 10 mg, orally)
Doxylamine succinate Sedaplus Saft (2.5 mg/ml) negative (max. single dose 30 mg, orally)
Gelatine polysuccinate Gelafundin 4% (40 mg/ml) ND
Clemastine fumarate Tavegil (0.4 mg/ml) negative (max. single dose 2 mg, i.v.)
Dimethindene maleate Fenistil (1 mg/ml) negative (max. single dose 4 mg, i.v.)
Succinic acid/Sigma-Aldrich, Munich, Germany (2.5 mg/ml) ND
S kin prick tests and challenge tests were performed with the commercial preparations unless otherwise indicated. ND = Not done; i.v. = intravenously.
Table 2.  Test results in patient 2
Agent Preparation Skin prick test Intradermal test Challenge test
Prednisolone sodium hemisuccinate Solu-Decortin (50 mg/ml) 12 mm (0.5 mg/ml) ND
Methylprednisolone sodium hemisuccinate Urbason solubile (16 mg/ml) 10 mm (0.16 mg/ml) ND
Triamcinolone acetonide dipotassium phosphate Volon A solubile (40 mg/ml) ND
Hydrocortisone sodium succinate Hydrocortison rotexmedica
(50 mg/ml)
ND
Succinic acid/Sigma-Aldrich, Munich, Germany (2.5 mg/ml) ND ND
Dexamethasone disodium phosphate Fortecortin  (10 mg/ml) ND ND negative (max. single dose 60 mg, i.v.)
Prednisolone Decortin H (50 mg) ND ND negative (max. single dose 50 mg, orally)
S kin prick tests and challenge tests were performed with the commercial preparations unless otherwise indicated. ND = Not done; i.v.= intravenously.
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tion to intradermal physiological saline (negative control); hista-
mine dihydrochloride (0.1%) yielded a strongly positive reaction 
(wheal diameter 8 mm) in the skin prick test.
 Basophil activation tests with peripheral blood cells from the 
patient and from two nonatopic controls without a history of cor-
ticosteroid hypersensitivity were done using the Basotest  (Orpe-
gen Pharma, Heidelberg, Germany). In brief, heparinized whole 
blood was incubated with PSH, HSS and hydrocortisone at differ-
ent concentrations as well as with fMLP (positive control) and 
Basotest stimulation buffer (negative control). Cells were double 
stained with a phycoerythrin-conjugated antibody to human IgE 
(identifying basophil granulocytes) and a fluorescein-conjugated 
antibody to glycoprotein gp53 (CD63) expressed on activated ba-
sophils. Cell characteristics were determined by flow cytometry. 
Analysis of the CD63 expression of the patient’s cells revealed sig-
nificant positive responses to PSH and HSS at various concentra-
tions but not to hydrocortisone ( fig. 1 ). There was no activation of 
basophils from the two controls.
 Because of the patient’s general condition and multiple con-
comitant diseases, he was not challenged with the incriminated 
drugs. However, intravenous challenges with dexamethasone di-
sodium phosphate (Fortecortin  Inject; maximum single dose 60 
mg) and oral challenges with prednisolone (Decortin H; maxi-
mum single dose 50 mg), which are both succinate-free, were per-
formed and well tolerated.
 Discussion 
 Skin prick or intradermal tests were positive to PSH 
and MSH in both patients – in patient 1 also to hydrocor-
tisone sodium succinate. A challenge test was done in pa-
tient 1 with PSH and MSH and caused systemic symp-
toms. Patient 2 was not challenged with the incriminated 
drugs because of his general condition and multiple con-
comitant diseases. Based on history and test results, we 
made a diagnosis of immediate-type hypersensitivity to 
certain corticosteroids, which, in view of positive skin 
and in vitro tests, probably has an immunological basis. 
Hypersensitivity was restricted to succinylated com-
pounds as various corticosteroids without the succinate 
moiety were tolerated well.
 To make corticosteroids water-soluble for intravenous 
application, they are often esterified with succinic acid, 
phosphoric acid or others, primarily at the C21 position 
 [23] . Especially succinate esters seem to have a sensitizing 
potential  [13] . Because of their low molecular weight, cor-
ticosteroids probably act as haptens  [24–26] .
 In patient 1, basophil activation tests using the Flow2 
CAST system remained negative. In patient 2, expression 
of the activation marker CD63 was induced on basophils 
by PSH and HSS but not by hydrocortisone; cells from 
two healthy controls showed no reaction. The positive ba-
sophil activation tests with cells from patient 2 corrobo-
rated the diagnosis of hypersensitivity to succinylated 
corticosteroids, particularly as challenge tests with the 
suspected agents could not be performed. The discrepant 
results of the basophil activation test obtained with cells 
from patient 1 or patient 2 may be related to the different 
methodology used, but cells from patients with definite 
IgE-mediated allergy do not always react to the respective 
allergen in this test system  [27–29] .
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 Fig. 1. Percentage of activated basophils from patient 2 and two unaffected controls after incubation with pred-
nisolone sodium succinate ( a ) and hydrocortisone sodium succinate  ( b ). There was no activation of basophils 
by hydrocortisone without the succinate moiety. 
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 It has been claimed that immediate-type hypersensi-
tivity reactions to corticosteroids could be triggered by 
nonimmunological mechanisms  [17] . In some of the cas-
es with negative prick tests, idiosyncrasy similar to reac-
tions to acetylsalicylic acid was suspected  [30] . In these 
cases, inhibition of cyclooxygenase is suggested to cause 
bronchospasm by blocking prostaglandin production 
which results in increased leukotriene production  [30, 
31] . Others suggested that some of these reactions, such 
as cardiovascular collapse, can be explained by rapid in-
fusion of a considerable amount of corticosteroids, caus-
ing a decrease in cardiac output, secondary to   -adrener-
gic blockade and a negative inotropic effect  [32, 33] .
 Asthma, nonsteroidal anti-inflammatory drug hyper-
sensitivity and multiple high-dose applications of corti-
costeroids in the past have been considered to be risk fac-
tors for immediate-type hypersensitivity to corticoste-
roids  [11] , which may also be encountered more often in 
patients with atopic conditions or renal transplants  [17] . 
However, these associations are vague, and current data 
do not support any unequivocal host factors that may 
predispose patients to corticosteroid hypersensitivity 
 [17] .
 In recent years, immediate-type hypersensitivity reac-
tions to succinylated corticosteroids have been described 
quite frequently  [3, 4, 6, 7, 9, 11, 12, 14–16, 18, 24–26, 34–
41] whereas such reactions to succinate-free corticoste-
roids seem to be less frequent  [2, 5, 10, 19, 20, 42–44] . A 
number of patients had positive skin prick tests to the 
eliciting and related corticoidsteroids  [11, 26, 45, 46] . Spe-
cific serum IgE antibodies to corticosteroids were dem-
onstrated in a few cases  [11, 24, 42] . 
 In agreement with our results, 4 patients who experi-
enced immediate-type reactions after administration of 
MSH, but who tolerated methylprednisolone without the 
succinate moiety well have been reported  [15, 16, 18] . 
Koutsostathis and Vovolis  [15] , for example, reported 1 
female patient who experienced an anaphylactic shock 
Table 3.  Synopsis of diagnostic results in published cases of systemic immediate-type hypersensitivity to succinylated corticosteroids
Eliciting agent 
(as given by the original authors)
Skin
prick test
Intradermal
test
Challenge test with
the eliciting agent
Other diagnostics Refer-
ence
Methylprednisolone hydrogen succinate 
(patient 1)
positive ND positive [18]
Methylprednisolone hydrogen succinate 
(patient 2)
negative positive ND
Methylprednisolone sodium succinate negative positive ND [16]
Methylprednisolone succinate positive positive ND demonstration of specific IgE antibodies
to methylprednisolone succinate negative
[15]
Hydrocortisone succinate ND ND ND [40]
Methylprednisolone sodium succinate ND positive ND [7]
Methylprednisolone sodium succinate positive positive ND [26]
Methylprednisolone sodium succinate ND positive ND [25]
Methylprednisolone sodium succinate negative positive ND [12]
Prednisolone sodium succinate positive ND ND [4]
Methylprednisolone sodium succinate positive positive ND [9]
Methylprednisolone sodium succinate positive ND ND demonstration of specific IgE antibodies to 
methylprednisolone sodium succinate positive
[11]
Methylprednisolone sodium hemisuccinate positive positive positive [35]
Hydrocortisone sodium succinate positive positive positive [14]
Hydrocortisone sodium succinate ND positive ND demonstration of specific IgE antibodies to 
hydrocortisone sodium succinate negative
[3]
Methylprednisolone sodium succinate ND positive ND scratch test positive [17]
Hydrocortisone hemisuccinate positive ND ND [38]
Methylprednisolone sodium succinate positive ND ND [6]
Prednisolone hemisuccinate negative positive
(in 3/4 patients)
ND demonstration of specific IgE antibodies to 
prednisolone hemisuccinate negative 
[39]
ND = Not done.
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after receiving MPS. Both, skin prick and intradermal 
tests were positive for MPS and hydrocortisone succinate. 
Koutsostathis and Vovolis challenged the patients only 
with nonsuccinylated corticosteroids. Challenge tests 
with succinylated corticosteroids (e.g. MPS) and other 
succinylated noncorticosteroid compounds were not per-
formed  [15] . In addition, we performed a basophil activa-
tion test. Besides our patients, there have been other cas-
es related to this topic ( table  3 ). However, it is not yet 
known how often corticosteroid hypersensitivity is re-
stricted to succinylated compounds as it seems that the 
type of esterification has not always been considered. Im-
mediate-type hypersensitivity to succinate salts as such 
has not been reported so far  [4] , nor have we found any 
reactions to succinic acid or other compounds than cor-
ticosteroids bearing the succinate moiety in patient 1. 
However, though the succinate fraction was comparable 
in doxylamine succinate (15.1 mg succinate per 50 mg), 
MSH (12.4 mg succinate per 50 mg) and PSH (12.8 mg 
succinate per 50 mg), the maximum allowed daily dose 
of doxylamine succinate was 50 mg whereas the admin-
istered doses of MSH or PSH were 100 or 166 mg, respec-
tively. Also, in contrast to intravenous challenge tests 
with succinylated corticosteroids, oral challenge tests 
were performed with succinylated noncorticosteroid 
compounds.
 Currently, anaphylactic reactions to other succinylat-
ed noncorticosteroid compounds in patients reporting 
immediate-type hypersensitivity to succinylated cortico-
steroids cannot be completely excluded. Though a chal-
lenge test with doxylamine succinate was well tolerated 
by one of our patients; it was just an oral challenge test 
with a low dose. Challenge tests with injectable succinyl-
ated noncorticosteroid compounds, in particular (e.g. 
gelatine polysuccinate), were not performed. Further 
studies have to clearly unravel this question.
 In summary, it is important to be aware of the possi-
bility of immediate hypersensitivity to corticosteroids in 
order to select treatment accordingly. Adequate allergo-
logical diagnosis is necessary in such patients not only to 
identify the culprit compound, but also to find a suitable 
corticosteroid for future intravenous treatment. Further-
more, such tolerated corticosteroids should be included 
in the patient’s emergency kit.
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